Drug development Efficacy tests Safety toxicty test Preclinical

의약품 등의 안전성 유효성 심사과정 Drug development Efficacy tests Safety (toxicty test) Preclinical test (In vitro/ In vivo ) Investigational new drug 연구용 신약(IND) Good Laboratory Practice(GLP) General toxicity tests Special toxicity tests 중앙약사 심의위원회 (임상시험/가교시험 조건부 신약허가) 임상시험심사위원회(Institutional Reviw Board) Clinical tests(1, 2, 3) Good Clinical Practice(GCP) Phase 1(Clinical pharmacology)-정상인 안전성, 체내동태 Phase 2(Clinical investigation)-대상환자 유효성 Phase 3(Clinical trials)-다수(90명↑) 용법, 용량, 주의사항 Approval for marketing Good manufacturing Practice(GMP) New drug application (신약승인신청) Phase 4(postmarketing clinical trials)-증례수집 시판 계속 / 중지

Product of Silymarin Milk thistle has not been evaluated by the FDA for safety, effectiveness, or purity

Action of Silymarin

*Clinical trials 논문 년도 내용 Study on dose linearity of the pharmacokinetics of silibinin diastereomers using a new stereospecifi c assay. Int J Clin Pharmacol Ther Toxicol 30: 134– 138. 1992 No side-effects were observed in volunteers following a single oral dose of silymarin corresponding to 254 mg Silybin Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J Hepatol 26: 871– 879. 1997 Patients with liver disorders of various origins who received oral silymarin(600– 800 mg/day) for 6 months did not manifest adverse. Effects 1996 Clinical trials involving about 3500 patients, of whom 2637 with liver disease, treated with Legalon (560 mg/day) for 8 weeks reported that the frequency of adverse effects with silymarin was about 1% Properties and medical use of fl avonolignans (Sylimarin) from Sylibum marianum. Phytother Res 10: S 25–S 26. * Preclinical data has not documented acute toxicity for Abenavoli, Raffaele Capasso, Natasa Milic and Francesco sylimarin and silybin. By Ludovico Capasso. REVIEW Milk Thistle in Liver Diseases: Past, Present, Future. . Res. 24: 1423– 1432